- Nonstatin Cholesterol Medications - NEXLIZET® NEXLETOL®
NEXLIZET is a combination of 2 medicines, bempedoic acid and ezetimibe The bempedoic acid portion of NEXLIZET was studied in a large clinical trial on reducing heart attack and heart procedures, like stent placement or bypass surgery, in adults who were unable to take recommended statin treatment
- Nexlizet: Uses, Dosage, Side Effects, Warnings - Drugs. com
Nexlizet may cause the following serious side effects Increased levels of uric acid in your blood (hyperuricemia) This can happen within 4 weeks of starting Nexlizet and can continue throughout your treatment Your healthcare provider may monitor your blood uric acid levels while taking Nexlizet High levels of blood uric acid may lead to gout
- Nexlizet: Dosage, side effects, uses, interactions, cost, and . . .
Dosage for reducing certain cardiovascular risks Nexlizet is approved to help reduce the risk of heart attack and coronary revascularization (a type of heart procedure) in certain adults
- Nexlizet (bempedoic acid ezetimibe) - Uses, Side . . . - WebMD
What is Nexlizet used for? Nexlizet (bempedoic acid ezetimibe) is commonly used for the following conditions Nexlizet should be stored at room temperature, between 68 F to 77 F (20 C to 25 C) It
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- Nexlizet (Bempedoic acid and Ezetimibe) for Heart Disease
Nexlizet is indicated as an adjunct therapy to diet and maximally-tolerated statin therapy Nexlizet is a combination treatment of two drugs, bempedoic acid and ezetimibe Bempedoic acid is a member of the adenosine triphosphate-citrate lyase (ACL) inhibitor class of drugs
- NEXLIZET® NEXLETOL® HCP Information - Official Site
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
- LABEL - Food and Drug Administration
NEXLIZET, which contains an adenosine triphosphate-citrate lyase (ACL) inhibitor and a cholesterol absorption inhibitor, is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require
|